United Therapeutics Corporation Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent
United Therapeutics Corporation (UTHR) reported Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent of $2.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent · last filed 2026-02-25
- United Therapeutics Corporation reclassification from aoci, current period, net of tax, attributable to parent for fiscal 2025 was $2.50M, a 127.27% increase from fiscal 2024.
- United Therapeutics Corporation reclassification from aoci, current period, net of tax, attributable to parent for fiscal 2024 was $1.10M.
- United Therapeutics Corporation reclassification from aoci, current period, net of tax, attributable to parent for fiscal 2021 was -$600.00K.
| Period end | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 12 month |
|---|---|
| 2025-12-31 | $2.50M 10-K · filed 2026-02-25 |
| 2024-12-31 | $1.10M 10-K · filed 2026-02-25 |
| 2021-12-31 | -$600.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |